 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Cardura, Carduran, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a693045 |
| Routes of administration | By mouth (tablets) |
| Drug class | α1-selective adrenergic blocker[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 65% |
| Protein binding | 98% |
| Metabolism | Liver |
| Elimination half-life | 22 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C23H25N5O5 |
| Molar mass | 451.483 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Doxazosin, sold under the brand names Cardura among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure.[1] For high blood pressure, it is a less preferred option.[1] It is taken by mouth.[1]
Common side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain.[1] Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism.[1][3] Prostate cancer should be ruled out before starting treatment.[1] It is a α1-selective adrenergic blocker in the quinazoline class of compounds.[1]
Doxazosin was patented in 1977 and came into medical use in 1988.[4] It is available as a generic medication.[3] A month supply in the United Kingdom costs the NHS about £0.50 as of 2019.[3] In the United States the wholesale cost of this amount is about US$5.50.[5] The modified-release form is more expensive without any particular advantage over the standard form.[6] In 2017, it was the 150th most commonly prescribed medication in the United States, with more than four million prescriptions.[7][8]
References edit
- ^ a b c d e f g h i "Doxazosin Mesylate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 5 October 2020. Retrieved 17 March 2019.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 26 October 2020. Retrieved 7 September 2020.
- ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 765. ISBN 9780857113382.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495. Archived from the original on 2019-12-22. Retrieved 2019-02-28.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
- ^ Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2019). The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (2nd ed.). Elsevier. pp. 26–27. ISBN 978-0-7020-7442-4. Archived from the original on 2021-05-22. Retrieved 2021-11-09.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Doxazosin Mesylate - Drug Usage Statistics". ClinCalc. Archived from the original on 5 October 2020. Retrieved 11 April 2020.